Tuberculosis Diagnosis and Treatment

Introduction to Tuberculosis

The American Thoracic Society recommends a standard 6-month treatment regimen with a combination of antibiotics for drug-susceptible cases, with directly observed therapy being essential to ensure compliance and prevent resistance 1, 2

The Centers for Disease Control and Prevention states that tuberculosis is primarily transmitted through the air by droplets and droplet nuclei containing the bacillus 2
Within the host, there are three subpopulations of M. tuberculosis: rapidly growing extracellular bacilli, slowly growing bacilli, and dormant bacilli 2
The frequency of spontaneous mutations that confer drug resistance varies by drug: approximately 10^-6 for isoniazid and streptomycin, 10^-8 for rifampicin, and 10^-5 for ethambutol 2

The standard treatment regimen for drug-susceptible tuberculosis consists of a 6-month regimen divided into two phases, as recommended by the American College of Chest Physicians:
- Intensive phase (2 months): isoniazid, rifampicin, pyrazinamide, and ethambutol 1
- Continuation phase (4 months): isoniazid and rifampicin 1
For extrapulmonary tuberculosis, a 6-month regimen is recommended for most cases, with exceptions, according to the American Thoracic Society:
- Tuberculous meningitis: 9-12 months of treatment 3
- Disseminated or miliary tuberculosis in children: 9-12 months of treatment 3
- Bone or joint tuberculosis in children: 9-12 months of treatment 3

For patients with HIV, the treatment duration should be at least 9 months, and directly observed therapy is especially important, as stated by the World Health Organization 2
For patients with renal insufficiency, dose adjustments are required for certain medications, and administration should be done after dialysis, according to the National Kidney Foundation 4
For patients with liver disease, close monitoring is necessary due to the risk of hepatotoxicity from isoniazid, rifampicin, and pyrazinamide, as recommended by the American Association for the Study of Liver Diseases 2

The treatment for multidrug-resistant tuberculosis (MDR-TB) should be individualized based on susceptibility studies and should be done in consultation with a tuberculosis expert, according to the Centers for Disease Control and Prevention 5, 1
Empiric regimens for MDR-TB cases may include a fluoroquinolone, an injectable agent, and an additional oral agent, as recommended by the World Health Organization 5, 6
Adding a single new medication to a failing regimen can lead to acquired resistance to the new drug, as stated by the American Thoracic Society 6